Parallel screening of FDA-approved antineoplastic drugs for identifying sensitizers of TRAIL-induced apoptosis in cancer cells

Table 1 Summary of drugs identified as TRAIL sensitizing agents and their previously known activity.

10 μM
Drug Name	Drug Alone	Drug Alone + TRAIL Alone (Additive)	Combination Treatment	p-Value	Known TRAIL Sensitizer?	Known TRAIL Sensitizer in Prostate Cancer?	Known TRAIL Sensitizer in Pancreatic Cancer?
Daunorubicin	47	51.3	95.6	< 0.01	Yes	No	No
Docetaxel	31.2	35.5	72.7	< 0.01	Yes	Yes	No
Doxorubicin	39	43.3	90.8	< 0.01	Yes	Yes	Yes
Epirubicin	34.7	39	58.7	< 0.05	Yes	Yes	No
Fludarabine	58.6	62.9	86.2	< 0.05	Yes	No	No
Idarubicin	53.3	57.6	97.7	< 0.01	No	No	No
Irinotecan	30.6	34.9	65.4	< 0.01	Yes	Yes	No
Mithramycin	28.6	32.9	95	< 0.01	Yes	Yes	No
Mitoxantrone	52.2	56.5	97.7	< 0.01	No	No	No
20 μM
Cladribine	0	4.1	38.5	< 0.05	No	No	No
Cytarabine	7.9	12.2	32.9	< 0.05	No	No	No
Gemcitabine	28.4	32.7	70.5	< 0.01	Yes	Yes	Yes
Thioguanine	4.7	9	40.8	< 0.05	No	No	No
Thiotepa	6.2	10.5	47.2	< 0.01	No	No	No

Values are listed as mean percent viability reduction. Leads employed in an expanded dose response are shown in bold font.

ISSN: 1471-2407